NovaDel Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NovaDel Pharma, Inc.
Sun enjoyed a sequential improvement in its US sales in Q2, with finished-dosage turnover in the market up by almost a fifth over the financial first quarter. Meanwhile, the Indian company is hoping to build on early momentum for its psoriasis therapy Ilumya in Japan, leveraging the dermatology expertise of acquired local company Pola.
Sun is hoping to build on early momentum for its psoriasis therapy Ilumya in Japan, leveraging the dermatology expertise of acquired local company Pola. The IL-23p19 inhibitor is also among the Indian firm's specialty products that saw US sales claw back to pre-COVID levels in Q2.
Warning letter objects to webpage and meeting exhibit material for excluding any risk information and suggesting mist formulation is superior to oral zolpidem products.
Research has shown that going without 7-8 hours of sleep each night takes a great toll on the human body, resulting in an increased risk for obesity, diabetes, cardiovascular disease, mental illness, cancer growth, Alzheimer's disease and other health problems, according to the National Institutes of Health (NIH).
- Drug Delivery